Classifications

• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B82—NANOTECHNOLOGY
  • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
  • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
  • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin

Definitions

• the present invention relates to inclusions of saturated A-ring steroids and their metabolites in cyclodextrins, inclusions which can take the form of complexes and which apply in particular to endogenous sex steroids. It also relates to a process for their manufacture.
• Steroids generally have very low water solubility, which makes their use very difficult, if not impossible in many cases, for example for their administration by intravenous route. It is known to increase the solubility of steroids by adding solubilizing agents such as lecithin, but this technique is unsatisfactory due to the chemical instability which results therefrom.
• steroids administered orally have poor bioavailability and a low dissolution rate.
• the present invention therefore relates more particularly to the dissolution of steroids comprising from 18 to 27 carbon atoms and having a saturated A nucleus. Furthermore, as will be seen below, the present invention applies very particularly to steroids of this type having:
• At least one alcohol and / or ketone and / or acid function in positions 3,7,11,12,14,17 or on said hydrocarbon chain, at least one alcohol and / or ketone and / or acid function. - optionally an acid radical in position 2.
• cycles B and C are always in the respective trans position and cycles C and D almost always also in the respective trans position.
• the present invention relates to steroids with a saturated cycle A, which excludes, for example, estrone or hydroxy-3-estratriene 1,3,5 (10) -one-17.
• the steroids targeted by the invention have from 18 to 27 carbon atoms and correspond to the general formula
• R 2 and R 3 is hydrogen, at least one of R 2 and R 3 being a methyl radical;
• R 4 is hydrogen, an alcohol or an aliphatic hydrocarbon chain optionally branched and optionally carrying one or more alcohol and / or ketone and / or acid functions;
• R 5 is a hydrogen atom or a radical
• R 4 and / or R 5 may be a ketone radical; an optionally aminated heterocycle can be formed between positions 2 and 3 by including the two corresponding carbon atoms and one or more nitrogen and optionally oxygen atoms. Furthermore, a methyl radical can be fixed in position 1 or 2, an acid radical can be fixed in position 2, and a double bond can exist between positions 5 and 6. A ketone function, and / or an alcohol function and / or a hydrogen can be fixed in positions 7 and / or 11 and / or 12.
• cyclodextrins As regards the cyclodextrins, it will be recalled that they are cyclic oligosaccharides generally composed of 6 to 8 units of glucoses
• alpha, beta, gamma cyclodextrin linked together by an alpha ⁇ 1-4 covalent bond.
• cyclodextrins to which the present invention makes use are in particular betacyclodextrin, gammacyclodextrin and hydroxypropyl betacyclodextrin, in whole or in part substituted.
• Cyclodextrins are characterized by the fact that the inner part of the molecules is apolar, while the outer part is polar.
• Steroids in aqueous solution or hydroalcoholic in a judiciously chosen ratio
• Figure 4 the solubility of the same dihydro-testosterone (mg / l) as a function of the concentration of hydroxypropylbétacyclodextrine dan water (10- 3 M);
• Figure 5 the solubility of progesterone dihydro-4- (mg / l) as a function of the concentration of beta-cyclodextrin in water (in 10- 3 M);
• FIG. 7 the solubility of pregnane-5-beta-ole-3-alpha-one-20 (in%) as a function of time in various cases compared;
• FIG. 8 the solubility of dihydro-4-testosterone (in%) as a function of time, in various cases compared;
• Betacyclodextrin solutions are produced at different concentrations from 0 to 5mM.
• pregnane-5-beta-3alpha-one-20 is added by pinching and this until a precipitate appears.
• Magnetic stirring is carried out at 25 ° for 72 hours, taking care to check at regular intervals that there is always saturation in steroids. After 72 hours, the solutions thus produced are filtered and the supernatant is assayed. The results obtained are the subject of the curve in FIG. 1.
• Example 2 the same protocol is followed as in Example 1 except that the concentration of hydroxypropybeta-cyclodextrin varies from 0 to 32 mM and the results are represented by the curve in FIG. 6.
• betacyclodextrin 0.5 gram of betacyclodextrin is dissolved in 50ml of water and 50mg of pregnane-5beta-ole-3alpha-one-20 in 50ml of 95% V / V ethanol.
• the two fractions are combined and placed under magnetic stirring for 30 minutes at approximately 25 ° C.
• the ethanol is evaporated.
• a precipitate forms.
• the remaining aqueous fraction and its precipitate are placed under magnetic stirring for 24 hours at 25 ° C. + 1 ° C.
• the solution is filtered.
• the water is removed; the powder thus obtained is homogenized.
• a dissolution is carried out on the complex after dosing the steroid level which is 5%. The results are illustrated by the curves in FIG.
• solubility curves are represented in FIG. 8 as in FIG. 7 the lower curve represents the solubility of the steroid alone, that is to say of dihydro-4-testosterone, the intermediate curve corresponds to the physical steroid + cyclodextrin mixture with the same remark as above, and the upper curve represents the solubility of the dihydro-4-testosterone / hydroxypropylbetacyclodextrin complex.
• the invention relates to the dosage forms of the products thus obtained and to the therapeutic applications of the active steroids thus included.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Nanotechnology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Biophysics (AREA)
• Biotechnology (AREA)
• General Engineering & Computer Science (AREA)
• Medical Informatics (AREA)
• Molecular Biology (AREA)
• Crystallography & Structural Chemistry (AREA)
• Epidemiology (AREA)
• Steroid Compounds (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=9400535

Family Applications (1)

Country Status (5)

Families Citing this family (6)

Citations (3)

Family Cites Families (1)

• 1990
  • 1990-09-21 FR FR9011687A patent/FR2667070A1/fr active Granted
• 1991
  • 1991-09-20 DE DE69128584T patent/DE69128584T2/de not_active Expired - Lifetime
  • 1991-09-20 EP EP91402511A patent/EP0477107B1/fr not_active Expired - Lifetime
  • 1991-09-20 WO PCT/FR1991/000742 patent/WO1992004917A1/fr unknown
  • 1991-09-20 AT AT91402511T patent/ATE161732T1/de not_active IP Right Cessation

Patent Citations (3)

Also Published As

Similar Documents

Legal Events